Physician profile
Patrick T Koo
NPI 1801152772
$9,065.01
in general payments reported to CMS, 2019-2025
30 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $830 · 2021: $1,213 · 2022: $1,201 · 2023: $1,749 · 2024: $1,701 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,159.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,266.00 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,747.42 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $1,041.95 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $765.37 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $564.36 | 2022-2025 | |
| Ardelyx, INC. | $458.79 | 2023-2025 | Ibsrela |
| Celgene Corporation | $335.52 | 2021-2024 | Zeposia |
| Pfizer INC. | $301.22 | 2019-2025 | |
| Gilead Sciences, INC. | $214.09 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $189.94 | 2020-2025 | Ocaliva |
| Lilly USA, LLC | $140.63 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $119.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $101.23 | 2023-2024 | Sucraid, Sucraid |
| Organon LLC | $98.42 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $94.73 | 2022-2024 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $92.13 | 2023-2025 | |
| Daiichi Sankyo INC. | $87.20 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $83.40 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.41 | 2023-2024 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $65.19 | 2025 | Iqirvo |
| Shionogi INC | $54.04 | 2019 | |
| Aimmune Therapeutics, INC. | $26.20 | 2023 | |
| Conmed Corporation | $24.48 | 2025 | Conmed Biliary |
| Dynavax Technologies Corporation | $24.03 | 2021 | |
| Alfasigma USA, INC. | $19.64 | 2020 | |
| Medtronic, INC. | $18.48 | 2025 | Nexpowder |
| Endo Pharmaceuticals INC. | $18.08 | 2019 | |
| Braintree Laboratories, INC. | $17.73 | 2025 | Suflave |
| Albireo Pharma, INC. | $14.83 | 2024 | Iqirvo |
| W. L. Gore & Associates, INC. | $13.98 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Koo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.